Investors & Media

Corporate Profile

Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Our lead product candidate, bexotegrast (PLN-74809), is an orally available small molecule designed to be a selective inhibitor of αvβ1 and αvβ6, two integrins that play key roles in multiple fibrotic pathways. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration for both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is currently conducting BEACON-IPF, a Phase 2b/3 trial of bexotegrast for the treatment of IPF and has completed INTEGRIS-PSC, a Phase 2a trial of bexotegrast for the treatment of PSC. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors.  Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody against integrin α7β1 targeting muscular dystrophies. In addition to clinical stage programs, Pliant has developed PLN-101325 an anti-integrin mAb of α7β1 currently in preclinical studies targeting muscular dystrophies.